List view / Grid view
12 February 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers have developed a new type of malleable, self-healing and fully recyclable "electronic skin" that has applications ranging from robotics and prosthetic development to better biomedical devices...
26 August 2021 | By Dave Cook (Blueberry Therapeutics), Dave Edwards (Blueberry Therapeutics)
It might be easy to dismiss non-life-threatening diseases of the skin or nail as trivial, but their impact on physical and mental wellbeing can be significant. Such diseases are obvious targets for topical treatments, but the lack of effective formulations means patients are often faced with the prospect of oral…
5 January 2022 | By Georgios A Sotiriou (Karolinska Institutet), Liv Eidsmo (Karolinska Institutet)
Effective vancomycin concentrations can be delivered locally to methicillin-resistant Staphylococcus aureus (MRSA)-infected sites of the skin with the use of miniaturised needles. This presents opportunities for targeted delivery of medication for focal skin diseases. Here, Georgios A Sotiriou and Liv Eidsmo of the Karolinska Institutet discuss some of them.
20 May 2014 | By Galderma
Galderma announced that ACTINICA® Lotion is now available for the prevention of non-melanoma skin cancer in high risk patients, including those who have had an organ transplant, undergone chemotherapy for malignant disease or have HIV/AIDS...
4 June 2017 | By Shashank Jain - Formulation Research Scientist at G&W Laboratories
EPR Editor Steve Bremer discusses drug delivery through the skin with Shashank Jain, Formulation Research Scientist at G&W Laboratories.
24 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers have shown how they utilise 3D bioprinting to control the distribution of melanocytes on a biomimetic tissue substrate, to produce human-like skin pigmentation...
28 January 2021 | By Victoria Rees (European Pharmaceutical Review)
According to a new study, vaccines delivered via skin scarification were better at inducing T cell activity in pre-clinical animal models.
27 April 2018 | By European Pharmaceutical Review
Groundbreaking technology could help soldiers on the battlefield and people with skin disorders...
2 August 2022 | By Hannah Balfour (European Pharmaceutical Review)
Phase II results suggest litifilimab safely and effectively reduces skin disease activity in cutaneous lupus erythematosus (CLE) patients.
14 February 2020 | By Victoria Rees (European Pharmaceutical Review)
The marketing license for ingenol mebutate gel (Picato) has been suspended by the MHRA due to studies showing an increased risk of skin malignancies from the drug.
7 June 2021 | By Hannah Balfour (European Pharmaceutical Review)
Over 50 percent of psoriatic arthritis patients treated with Tremfya® (guselkumab) achieved ≥20 percent improvement in joint symptoms and complete skin clearance at one year.
5 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A new type of skin patch that administers drugs directly into the bloodstream is being tested as a possible answer to the antibiotic resistance crisis...
1 July 2016 | By Victoria White, Digital Content Producer
AstraZeneca has entered into an agreement with LEO Pharma for the global licence to tralokinumab in skin diseases.
7 March 2016 | By Victoria White (European Pharmaceutical Review)
New late-breaking data from Novartis’ head-to-head CLEAR study demonstrates that Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in achieving sustained skin clearance (PASI 90 response) at 52 weeks for adults living with moderate-to-severe psoriasis.
14 August 2024 | By Catherine Eckford (European Pharmaceutical Review)
The biologic treatment targets a key driver of prurigo nodularis, with trial data demonstrating improved itch as well as skin nodules for patients with the condition.
